Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 15/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470777 | 0.90 | PKM (0.65) | SLC6A7USP2MAPTMAPK1ALDH1A1 | |
| SCHEMBL3473795 | 0.88 | RXRA (0.49) | SLC6A7USP2MAPTMAPK1TSHR | |
| SCHEMBL3471846 | 0.88 | RXRA (0.51) | SLC6A7MAPTALDH1A1RXRANR1H2 | |
| SCHEMBL3471504 | 0.88 | KDM4E (0.52) | USP2MAPTMAPK1ALDH1A1TSHR | |
| SCHEMBL3472568 | 0.88 | RXRA (0.51) | SLC6A7MAPTMAPK1ALDH1A1RXRA | |
| SCHEMBL3470736 | 0.88 | RXRA (0.56) | SLC6A7MAPTMAPK1RXRANR1H2 | |
| SCHEMBL3472549 | 0.88 | RXRA (0.56) | MAPTMAPK1TSHRRXRANR1H2 | |
| SCHEMBL3474954 | 0.87 | SLC6A7 (0.57) | SLC6A7MAPTMAPK1ALDH1A1RXRA | |
| SCHEMBL3471233 | 0.87 | RXRA (0.56) | SLC6A7ALDH1A1RXRANR1H2NR1H3 | |
| SCHEMBL3472038 | 0.87 | RXRA (0.58) | SLC6A7MAPTALDH1A1RXRANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | SLC6A7 3064/4885USP2 4131/4885MAPT 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.